Transanal Versus Laparoscopic Total Mesorectal Excision: a Cohort
1 other identifier
observational
2,502
0 countries
N/A
Brief Summary
The purpose of this study was to compare the long-term oncology outcomes and specimen quality of taTME and laTME in the treatment of middle and low rectal cancer by a large sample cohort. At the same time, the local recurrence following a primary rectal cancer resection was analyzed to respond to the concerns about the event of the national suspension for TaTME due to the high local recurrence rate in Norway.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2014
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2022
CompletedFirst Submitted
Initial submission to the registry
December 27, 2022
CompletedFirst Posted
Study publicly available on registry
January 12, 2023
CompletedJanuary 12, 2023
December 1, 2022
8.8 years
December 27, 2022
December 27, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Overall survival rate
5 years after the surgery
disease-free survival ratev
5 years after the surgery
Secondary Outcomes (5)
Local recurrence rate
3 years after the surgery
Cancer special survival rate
5 years after the surgery
Quality of the mesorectum specimen
30 days after the surgery
CRM status
30 days after the surgery
DRM status
30 days after the surgery
Study Arms (2)
taTME
patients who underwent transanal total mesorectal excision
laTME
patients who underwent laparoscopic total mesorectal excision
Interventions
transanal TME
Eligibility Criteria
Low-mid rectal cancer within Stage III.
You may qualify if:
- Age between 18 and 80 years old
- Confirmed rectal adenocarcinoma cancer pathologically
- Tumor location ≦ 12 cm from the anal margin
- Willing and able to provide written informed consent for participation in this study
You may not qualify if:
- Distant metastasis before surgery
- More than one colorectal tumor at diagnosis
- Familial adenomatous polyposis
- Recurrent rectal cancer
- Undergo transanal minimally invasive surgery
- Undergo palliative treatment
- Undergo emergency surgery
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Li Z, Liu H, Luo S, Hou Y, Zhou Y, Zheng X, Zhang X, Huang L, Zeng Z, Kang L. Long-term oncological outcomes of transanal versus laparoscopic total mesorectal excision for mid-low rectal cancer: a retrospective analysis of 2502 patients. Int J Surg. 2024 Mar 1;110(3):1611-1619. doi: 10.1097/JS9.0000000000000992.
PMID: 38091943DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Liang Kang
Sun Yat-sen University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
December 27, 2022
First Posted
January 12, 2023
Study Start
January 1, 2014
Primary Completion
October 1, 2022
Study Completion
October 1, 2022
Last Updated
January 12, 2023
Record last verified: 2022-12